Secuenciación en cáncer de mama avanzado HER2+ - page 25

Conclusiones

• AntiHER2 + tratamiento hormonal superior a tratamiento hormonal 1ªL

• Trastuzumab + QT (taxano, VNR) impacto SLP y SG sobre QT sola

• Lapatinib + QT inferior a Trastuzumab + QT en 1ªL

•

Pertuzumab + Trastuzumab + QT 1ªL estándar en todos los subgrupos

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,15,16,17,18,19,20,21,22,23,24 26,27,28,29,30,31,32,33,34,35,...60